RET and lung carcinoma: In the LIBRETTO-001 trial, the authors reported that NSCLC patients with CNS metastases had over 82% objective intracranial response rate (18/22 patients), with two patients undergoing complete response, indicating that selpercatinib can penetrate the BBB to act upon brain metastases of RET-altered lung cancers (265, 267).